Status:
RECRUITING
Rapid Autopsy and Procurement of Cancer Tissue
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Thymus Tumors
Adoptive Cellular Therapy
Eligibility:
All Genders
18-120 years
Brief Summary
Background: \- Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disea...
Detailed Description
Background: * Despite being the leading cause of cancer-related death worldwide, there is only limited knowledge of tumor heterogeneity in lung cancer. There is also limited knowledge of tumor hetero...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients must have histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma confirmed by the NCI Laboratory of Pathology. Patients with bladder cancer (including urothelial carcinoma and other rare bladder or kidney histology), ovarian cancer, epithelial cancers (breast, colorectal, pancreatic, stomach and biliary cancers) and malignancies previously treated with an ACT are also eligible.
- Age \>= 18 years.
- Incurable disease or terminal diagnosis.
- Patients or legally authorized representative (LAR) must sign an informed consent indicating that they are aware of the investigational nature of this study.
- Patients must provide valid written designation of an assigned Durable Power of Attorney (DPA). If one is not available, an LAR must be assigned.
- Patients and their legal next of kin must agree to a Do Not Resuscitate (DNR) order and agree to Consent for Autopsy as part of the end-of-life care plan.
- EXCLUSION CRITERIA:
- Women known to be pregnant (known positive pregnancy test, although such testing is not required for enrollment) are excluded.
- Known HIV-positive patients will be excluded (although HIV testing is not required for enrollment) because of the potential for contamination of tissue.
Exclusion
Key Trial Info
Start Date :
December 30 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT01851395
Start Date
December 30 2013
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892